Vortioxetine is a serotonin modulating antidepressant indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the...
- Mechanism
- Curator reviewed
Vortioxetine is classified as a serotonin modulator and simulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, while also acting as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors.
- Primary indication
- Vortioxetine is indicated for the treatment of major depressive disorder (MDD).Curator reviewed · 1 structured indication
- Formula / weight
- C18H22N2S · 298.45 g/mol (avg)
- First approval
- Canada, 2014 · United States, 2013 · European Union, 2021
- Code names
- Lu-AA21004
- Brand names
Resolves to
YQNWZWMKLDQSAC-UHFFFAOYSA-NSMILESCC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1What you can answer from here — as of September 16, 2026
Which drugs share a target with Vortioxetine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account